Long-Term Maintenance on Weekly Semaglutide

A responsible read on semaglutide long-term & maintenance starts with mechanism, side effects, access, and monitoring rather than promises. That frame keeps the discussion useful for patients without pretending the evidence is stronger than it is.

A patient I work with, a 48-year-old physical therapist in Tampa named Lisa, hit her target weight nine months into semaglutide therapy. She sat in our telehealth follow-up, visibly relieved, and then asked the question I now hear more than any other: “So… what now? Do I just keep doing this forever?” She wasn’t asking about the drug’s mechanism. She was asking about her life. And that question, the “what now” of maintenance, is where the clinical conversation gets genuinely interesting and genuinely uncomfortable, because the honest answer is part data and part judgment call.

Most of the public discussion about semaglutide still focuses on the weight-loss phase. The titration, the nausea stories, the before-and-after photos. But for patients who’ve actually reached their goals, the maintenance phase is where the real decisions live. And the data we have, while solid, doesn’t hand us a neat protocol.

What “Maintenance” Means (and What It Doesn’t)

Maintenance on weekly semaglutide is the phase after a patient has reached their initial therapeutic target, whether that’s a goal weight, a hemoglobin A1c number, or some combination of metabolic markers their clinician is tracking. It’s its own clinical phase with its own set of questions: What dose do I stay on? For how long? Can I taper? What happens if I stop?

The two datasets that anchor most of this conversation are STEP-4 and STEP-5. STEP-5 (Garvey et al.) followed patients for 104 weeks on continuous semaglutide 2.4 mg and showed sustained weight reduction with a consistent safety profile across the full two years. STEP-4 (Rubino et al.) is the more sobering one: patients who were switched to placebo after an initial lead-in period on semaglutide experienced significant weight regain. That result shapes every honest maintenance conversation.

The boring truth is that for many patients, semaglutide in the maintenance phase looks a lot like semaglutide in the active-loss phase, just with the dramatic weekly scale changes flattened out. You’re still injecting. You’re still managing side effects (though they typically fade). You’re still paying for the medication. The difference is psychological: you’re holding ground instead of gaining it.

How the Drug Works (and Why That Matters for Maintenance)

Semaglutide is a GLP-1 receptor agonist with a half-life long enough to support once-weekly subcutaneous dosing. GLP-1 is an incretin hormone released by intestinal L-cells after you eat. The receptor shows up in three places that matter clinically: pancreatic beta cells (insulin secretion), the hypothalamus (appetite regulation), and the GI tract (gastric emptying).

What this means in practice is a four-pronged effect: glucose-dependent insulin secretion goes up, postprandial glucagon comes down, the stomach empties more slowly, and subjective hunger decreases through central signaling. The STEP-1 trial (Wilding et al., New England Journal of Medicine, 2021) randomized 1,961 adults with overweight or obesity, without diabetes, to 2.4 mg weekly semaglutide or placebo for 68 weeks. The semaglutide group lost approximately 14.9% of body weight versus 2.4% on placebo. STEP-3 added intensive behavioral therapy and the effect was directionally similar, somewhat larger. STEP-5 extended follow-up to 104 weeks.

On the diabetes side, the SUSTAIN program established glycemic and cardiovascular benefits at the lower dose range (0.5 mg, 1.0 mg, and later 2.0 mg in SUSTAIN FORTE). SUSTAIN-6 (Marso et al.) reported a reduction in major adverse cardiovascular events in high-risk diabetes patients.

Here’s the part that matters for maintenance: all those appetite and metabolic effects are drug-dependent. They don’t “train” your body to behave differently after you stop. Think of it like blood pressure medication. Lisinopril doesn’t teach your vasculature to relax on its own; it relaxes it while you take it. Semaglutide suppresses appetite and improves metabolic signaling while you take it. When you stop, the underlying physiology reasserts itself. That’s not a failure of the drug. It’s just what the drug is.

Dose, Titration, and the Maintenance Conversation

The standard titration schedule from the STEP trials (and the Wegovy label) runs through five steps: 0.25 mg weekly for four weeks, 0.5 mg for four, 1.0 mg for four, 1.7 mg for four, and then 2.4 mg as the maintenance dose. Sixteen to seventeen weeks to reach the top, if you tolerate every step on schedule.

Compounded programs generally follow the same milligram steps, though the concentration and injection volume differ by pharmacy. What matters clinically is the milligram dose, not how many units you draw into the syringe. If you’re switching between programs, confirm milligrams at every step. Don’t assume the volume is the same.

The schedule can pause at any rung. A patient struggling with nausea at 0.5 mg can sit there for an extra four weeks. A patient doing well clinically on 1.7 mg can elect to stay rather than push to 2.4 mg. This is a clinical decision, not a checkbox.

In the maintenance phase, some patients hold at 2.4 mg indefinitely. Others step down to 1.7 mg or 1.0 mg once weight has stabilized. I’ll be direct about this: the lower maintenance doses have not been studied with the same rigor as 2.4 mg, and I think clinicians and patients should acknowledge that uncertainty rather than pretend it doesn’t exist. The STEP-4 discontinuation data makes a reasonable case that some ongoing pharmacologic support is needed for most patients, but whether that means full-dose for life is a genuinely open question.

Side Effects: What Persists and What Fades

GI side effects dominate the safety profile: nausea, diarrhea, constipation, vomiting, abdominal discomfort. These were reported across both the STEP and SUSTAIN programs and match what clinicians see in practice. The pattern is familiar. Most events are mild to moderate, concentrated in the first eight to twelve weeks, and resolve with continued therapy or temporary dose adjustment.

What’s less commonly discussed is the side-effect profile in the maintenance phase specifically. Most patients who make it through the titration find GI symptoms manageable or resolved by the time they’re holding at their maintenance dose. The exceptions tend to involve patients who’ve had dose increases after a period of stability, or patients who’ve had concurrent dietary changes (a holiday buffet on a 2.4 mg stomach is an education nobody forgets).

The less common but clinically serious events: gallbladder problems (especially with rapid weight loss), acute pancreatitis (rare, but persistent severe abdominal pain radiating to the back demands evaluation), and the theoretical thyroid C-cell tumor signal from rodent studies that hasn’t been replicated in humans. Both the Wegovy and Ozempic labels carry a boxed warning on that rodent finding, with a contraindication for patients with personal or family history of medullary thyroid carcinoma or MEN2.

Hypoglycemia is uncommon in non-diabetic patients because semaglutide’s insulin effect is glucose-dependent. The risk increases when it’s stacked with insulin or sulfonylureas in diabetic patients, where dose adjustment of those agents is the relevant safety move.

Two-year safety data at the 2.4 mg dose, from STEP-5, shows a consistent signal. Cardiovascular safety in the diabetes population is supported by SUSTAIN-6. For compounded preparations specifically, the long-term safety data is less direct and depends partly on the manufacturing quality of the source pharmacy.

Cost, Access, and What You’re Actually Paying For

Brand-name Wegovy and Ozempic list north of $1,300 per month in the U.S. Cash-pay at most retail pharmacies lands between $1,000 and $1,400. Insurance coverage for weight management indications remains inconsistent; the diabetes indication fares better but still varies by plan.

Compounded semaglutide programs in compliant telehealth structures price substantially below that. HealthRX, for instance, runs $179.99 to $279.99 per month depending on dose, available in 44 states, and operated under LegitScript certification.

The gap is real and structural. Brand-name products carry the full cost of manufacturing scale-up, regulatory submissions, post-marketing surveillance, and the commercial margin that funds the next generation of research. Compounded preparations use a different regulatory pathway with a different cost structure. That’s not an argument for one over the other. It’s an explanation of why the numbers differ.

The comparison between compounded and brand-name semaglutide comes down to supply pathway, not active ingredient. Brand-name products have registrational trial data behind them, an FDA-approved label, and industrial-scale manufacturing from Novo Nordisk. Compounded preparations contain the same molecule, are prepared by state-licensed or 503A compounding pharmacies for individual patients, and are not FDA-approved as finished products. The clinical evidence from STEP and SUSTAIN was built on brand-name product. It informs but does not directly extend to compounded preparations. The manufacturing oversight model differs. The adverse-event surveillance system is less complete.

None of that means compounded semaglutide is unsafe by default. It means the frameworks are different, and a good program names those differences at intake rather than burying them.

If you’re using HSA or FSA funds, confirm the invoicing format your program provides before enrolling. Plans vary on what documentation they’ll accept.

The Part Nobody Wants to Talk About

Patients moving into maintenance deserve a reference that addresses long-term dosing and the question of eventual discontinuation without the marketing gloss that fills most search results. A solid guide on semaglutide long-term & maintenance covers mechanism, dosing schedule, and patient-level safety without trying to sell you something. It’s background reading that makes the clinical conversation more productive, not a replacement for it.

The part nobody wants to talk about is this: for a meaningful subset of patients, semaglutide maintenance is indefinite. Not because the drug is addictive, but because obesity is a chronic condition with a strong biological basis, and the pharmacologic intervention is managing that biology. The STEP-4 data makes this uncomfortable reality clear. Patients who stopped regained. Not all of them, and not all the weight, but the trend was unmistakable.

My genuinely opinionated take: the framing of semaglutide as something you “graduate from” is doing patients a disservice. We don’t tell patients with hypertension they should plan to stop amlodipine once their blood pressure is controlled. The maintenance conversation should start with the assumption of ongoing therapy, and taper or discontinuation should be the thing that requires justification, not the other way around.

When to Contact Your Clinician

Several situations call for a direct conversation rather than self-management. Persistent severe abdominal pain, especially with radiation to the back or fever. Inability to keep fluids down for more than 24 hours, signs of dehydration, persistent vomiting. New gallbladder symptoms (right upper quadrant pain after meals, jaundice). New or worsening reflux that doesn’t respond to meal-timing changes. Mood changes, including new or worsening depressive symptoms.

Pregnancy, planned pregnancy, or breastfeeding: talk to your clinician before the next dose. Personal or family history of medullary thyroid carcinoma or MEN2 is a hard contraindication and should have been caught at intake. If it wasn’t, raise it immediately.

Patients on insulin, sulfonylureas, warfarin, or other medications with narrow therapeutic windows should discuss potential interactions, particularly the slowed gastric emptying that can affect absorption of concurrent medications.

Frequently Asked Questions

How long do I stay on therapy? Individualized, but STEP-5 supports two years of continuous therapy with consistent safety. Many patients continue beyond that under clinician supervision. The default expectation should be ongoing treatment, with discontinuation as the exception requiring clinical rationale.

Can I step down to a lower dose? Some patients hold at 1.7 mg or 1.0 mg during maintenance. These lower maintenance doses haven’t been studied with the same rigor as 2.4 mg. It’s a clinical judgment, not a protocol.

What happens if I stop? STEP-4 showed significant weight regain after switching to placebo. Real-world experience matches that. The degree of regain depends partly on the lifestyle changes consolidated during therapy.

Is there a standardized taper? No. Some clinicians extend the dosing interval, some reduce the dose stepwise, some discontinue directly. The right approach is the one negotiated with your prescriber.

Will my appetite return? Most patients report appetite returning toward baseline within weeks of stopping. The behavioral patterns built during therapy (portion awareness, meal timing, food choices) are what determine the trajectory after that.

Is compounded semaglutide the same as Wegovy? Same active molecule, different supply pathway. Brand-name products have FDA approval as finished products and registrational trial data. Compounded preparations are made by licensed compounding pharmacies and are not FDA-approved as finished products.

Can I switch between brand-name and compounded during maintenance? Technically yes, but confirm the milligram dose at each transition. Volume and concentration differ between products.

References: Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 2021;384:989-1002 (STEP-1). Wadden TA et al. STEP-3. Rubino DM et al. STEP-4. Garvey WT et al. STEP-5. Davies M et al. STEP-2. SUSTAIN-6 (Marso SP et al.). Wegovy and Ozempic prescribing information (Novo Nordisk).

Important Notice

Not FDA-approved. Compounded semaglutide is prepared by licensed compounding pharmacies for individual patients based on a prescriber’s clinical judgment. This article is educational and does not constitute medical advice. Individual results vary.